Automate Your Wheel Strategy on URGN
With Tiblio's Option Bot, you can configure your own wheel strategy including URGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol URGN
- Rev/Share 1.9373
- Book/Share -0.9797
- PB -19.4555
- Debt/Equity -2.6895
- CurrentRatio 5.6471
- ROIC -0.5343
- MktCap 880596778.0
- FreeCF/Share -2.2646
- PFCF -8.1997
- PE -6.5294
- Debt/Assets 0.5046
- DivYield 0
- ROE -974.8662
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | URGN | H.C. Wainwright | Neutral | Buy | -- | $50 | June 16, 2025 |
| Downgrade | URGN | H.C. Wainwright | Buy | Neutral | -- | -- | May 22, 2025 |
| Initiation | URGN | Scotiabank | -- | Sector Outperform | -- | $23 | April 16, 2025 |
| Resumed | URGN | Ladenburg Thalmann | -- | Buy | -- | $31 | Feb. 19, 2025 |
| Initiation | URGN | Guggenheim | -- | Buy | -- | $40 | Aug. 22, 2024 |
News
URGN Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Lawsuit Against UroGen Pharma Ltd.
Published: May 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired UroGen Pharma Ltd. (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025.
Read More
URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm
Published: May 30, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm.
Read More
Levi & Korsinsky Investigates UroGen Pharma Ltd. (URGN) Over Possible Securities Fraud
Published: May 30, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA's Briefing Document and Subsequent ODAC Vote Against UGN-102 – Hagens Berman
Published: May 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, May 30, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Cockrell v. UroGen Pharma Ltd. et al., No. 3:25-cv-06088 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired UroGen securities between July 27, 2023 and May 15, 2025.
Read More
URGN BREAKING NEWS: UroGen Pharma Ltd. Stock Plummets 45% Triggering Shareholder Class Action – Contact BFA Law if You Lost Money (NASDAQ:URGN)
Published: May 30, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)---- $URGN #Attorney--Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ: URGN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in UroGen you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/urogen-pharma-ltd-class-action-lawsuit. Investors have until July 28, 2025, to ask the Court.
Read More
Ongoing Securities Investigation into UroGen Pharma Ltd. (URGN) - Contact Levi & Korsinsky
Published: May 30, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
Levi & Korsinsky Investigates Possible Securities Fraud by UroGen Pharma Ltd. (URGN)
Published: May 30, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
URGN Investors Have the Opportunity to Lead the UroGen Pharma Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
Published: May 30, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In UroGen To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in UroGen between July 27, 2023 and May 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , May 30, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against UroGen Pharma Ltd.
Read More
URGN Stockholder Alert: Robbins LLP Informs Investors of the UroGen Pharma Ltd. Class Action Lawsuit
Published: May 29, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , May 29, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired UroGen Pharma Ltd. (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025.
Read More
UroGen Pharma Ltd. Investors: Please contact the Portnoy Law Firm to recover your losses.
Published: May 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
Investors can contact the law firm at no cost to learn more about recovering their losses
Read More
URGN INVESTOR ALERT: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: May 29, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , May 29, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of UroGen Pharma Ltd. (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, inclusive (the "Class Period"), have until July 28, 2025 to seek appointment as lead plaintiff of the UroGen class action lawsuit.
Read More
Did You Suffer Losses in UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky About Securities Fraud Claims
Published: May 29, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny - Hagens Berman
Published: May 29, 2025 by: PRNewsWire
Sentiment: Neutral
URGN Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO , May 29, 2025 /PRNewswire/ -- On May 21, 2025, investors in UroGen Pharma Ltd. (NASDAQ: URGN) saw the price of their shares crash 44% after the company announced that the FDA's Oncologic Drugs Advisory Committee ("ODAC") voted against the risk/benefit profile of UroGen's UGN-102, a therapy intended to treat patients with low-grade, intermediate-risk non-muscle invasive bladder cancer ("LG-IR-NMIBC") for which no drugs are currently FDA-approved.
Read More
Lost Money on UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky About Fraud Investigation
Published: May 29, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
UroGen Pharma Ltd. (URGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Published: May 29, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of UroGen Pharma Ltd. ("UroGen" or "the Company") (NASDAQ:URGN).
Read More
Levi & Korsinsky Investigating Whether UroGen Pharma Ltd. (URGN) Misled Investors - Securities Law Violations Possible
Published: May 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating UroGen Pharma Ltd. (URGN) And Encourages Investors to Connect
Published: May 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of UroGen Pharma Ltd. ("UroGen" or "the Company") (NASDAQ:URGN).
Read More
Did UroGen Pharma Ltd. (URGN) Mislead Investors?
Published: May 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
Investigation Alert: UroGen Pharma Ltd. (URGN) Under Scrutiny - Contact Levi & Korsinsky for Details
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny – Hagens Berman
Published: May 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, May 27, 2025 (GLOBE NEWSWIRE) -- On May 21, 2025, investors in UroGen Pharma Ltd. (NASDAQ: URGN) saw the price of their shares crash 44% after the company announced that the FDA's Oncologic Drugs Advisory Committee (“ODAC”) voted against the risk/benefit profile of UroGen's UGN-102, a therapy intended to treat patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (“LG-IR-NMIBC”) for which no drugs are currently FDA-approved.
Read More
Did You Suffer Losses in UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky About Securities Fraud Claims
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. ("UroGen" or the "Company") (NASDAQ:URGN).
Read More
Lost Money on UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky to Protect Your Rights
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages UroGen Pharma Ltd. (URGN) Stockholders to Inquire about Securities Investigation
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of UroGen Pharma Ltd. ("UroGen" or "the Company") (NASDAQ:URGN).
Read More
ATTENTION UroGen Pharma Ltd. (URGN) Investors: Possible Fraud - Contact Levi & Korsinsky Today
Published: May 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
UroGen Pharma Stock Receives Downgrade As Analyst Cites FDA Panel Setback For Key Bladder Cancer Drug
Published: May 25, 2025 by: Benzinga
Sentiment: Negative
HC Wainwright & Co. analyst Raghuram Selvaraju downgraded the rating on UroGen Pharma Ltd. URGN from Buy to Neutral.
Read More
Ongoing Securities Investigation into UroGen Pharma Ltd. (URGN) - Contact Levi & Korsinsky
Published: May 23, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny - Hagens Berman
Published: May 23, 2025 by: Accesswire
Sentiment: Neutral
URGN Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO, CA / ACCESS Newswire / May 23, 2025 / On May 21, 2025, investors in UroGen Pharma Ltd. (NASDAQ:URGN)saw the price of their shares crash 44% after the company announced that the FDA's Oncologic Drugs Advisory Committee ("ODAC") voted against the risk/benefit profile of UroGen's UGN-102, a therapy intended to treat patients with low-grade, intermediate-risk non-muscle invasive bladder cancer ("LG-IR-NMIBC") for which no drugs are currently FDA-approved.
Read More
Potential Securities Fraud: Levi & Korsinsky Investigates UroGen Pharma Ltd. (URGN)
Published: May 23, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
UroGen Pharma Ltd. (URGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Published: May 23, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of UroGen Pharma Ltd. ("UroGen" or "the Company") (NASDAQ:URGN).
Read More
About UroGen Pharma Ltd. (URGN)
- IPO Date 2017-05-04
- Website https://www.urogen.com
- Industry Biotechnology
- CEO Elizabeth A. Barrett
- Employees 234